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Background: Cerebral edema is a well-recognized and potentially fatal complication of acute liver failure (ALF). The
effectiveness of treatments that address intracranial hypertension is generally assessed by measuring intracranial
pressure (ICP). The aim of this study was to determine the role of cerebral microdialysis in monitoring the efficacy
of fractionated plasma separation and adsorption (FPSA) treatment for ALF. We hypothesized that in ALF cerebral
microdialysis reflects the benefits of FPSA treatment on cerebral edema before ICP.
Methods: A surgical resection model of ALF was used in 21 pigs. We measured plasma ammonia concentration,
brain concentrations of glucose, lactate, pyruvate, glutamate and glutamine, and ICP. Animals were randomized
into three groups: in one group eight animals received 6 hours of FPSA treatment 2 hours after induction of ALF; in
another group 10 animals received supportive treatment for ALF only; and in the final group three underwent
sham surgery.
Results: The ICP was significantly higher in the ALF group than in the FPSA group 9 hours after surgery. The
lactate/pyruvate (L/P) ratio was significantly lower in the FPSA group than the ALF group 5 hours after surgery,
before any significant difference in ICP was detected. Indeed, significant changes in the L/P ratio could be observed
within 1 hour of treatment. Glutamine levels were significantly lower in the FPSA group than the ALF group
between 6 hours and 10 hours after surgery.
Conclusions: Brain lactate/pyruvate ratio and concentration of glutamine measured by cerebral microdialysis
reflected the beneficial effects of FPSA treatment on cerebral metabolism more precisely and rapidly than ICP in
pigs with fulminant ALF. The role of glutamine as a marker of the efficacy of FPSA treatment for ALF appears
promising, but needs further evaluation.
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Hepatic encephalopathy, causing increased intracranial
pressure (ICP) and brain injury, is a well-known and
potentially fatal complication of acute liver failure (ALF)
[1]. Orthotopic liver transplantation remains the only
treatment for fulminant ALF that significantly improves
the chances of survival [2]. A variety of approaches may
be taken to meet homeostatic needs during the critical
period when a donor organ is sought (bridging therapy).
Supportive therapy using fractionated plasma separation
and adsorption (FPSA) appears to have a beneficial effect
on intracranial hypertension [3]. The efficacy of FPSA
therapy in treatment of ALF-related brain injury is usu-
ally monitored by measuring ICP. Recently, the potential
of using cerebral microdialysis to monitor cerebral
metabolism has been explored in patients with ALF [4],
as has the effect of FPSA on the intracerebral oxidative
metabolism in ALF [5]. To date, one clinical trial has
reported that FPSA had no effect on brain metabolism
as measured by the lactate to pyruvate (L/P) ratio,
although the patient cohort was small and comprised
patients with different etiologies of ALF [5]. There have
been no studies in large animal models.
The objective of this trial was to evaluate the role of
cerebral microdialysis in monitoring FPSA therapy in a
well-defined pig model of ALF, and compare it with
intracerebral pressure (ICP), a parameter used more fre-
quently in clinical practice. We hypothesized that micro-
dialysis parameters would reflect the benefit of FPSA
treatment on brain injury in ALF earlier than ICP. Our
secondary outcome measure was to examine the influ-
ence of intracerebral glutamine concentration as a
marker of the therapeutic efficacy of FPSA.
Methods
The surgical resection model of ALF was undertaken in
23 pigs weighing 35–40 kg. This modified model [6]
combined 70% resection of the hepatic parenchyma and
20 min total venous hepatic occlusion. Two hours after
surgery, 20 animals were randomized into a control
group (ALF group) and a group treated by FPSA (FPSA
group). The animals in the FPSA group were connected
to the elimination device (Prometheus system, Fresenius
Medical Care AG, Germany), as described below, for 6
hours of treatment 2 hours after surgery had been com-
pleted [7]. In the SHAM group (three animals) a laparot-
omy alone was performed. Twelve hours after surgery,
all animals were euthanized by a lethal dose of thiopen-
tal (sodium pentothal, Abbott Laboratories, UK) and
7.45% potassium chloride (Braun). In the FPSA group,
two animals died postoperatively as a consequence un-
controllable hemorrhage. In total, 21 animals (10 in the
control group, 8 in the FPSA treated group and 3 in the
SHAM group) completed the study.Anesthesia
Animals were premedicated with intramuscular keta-
mine 10 mg/kg (Narkamon, Léčiva, Prague, Czech
Republic), atropine 0.01 mg/kg (Atropin Biotika,
Hoechst-Biotika, Martin, Slovakia), azaperone 4 mg/kg
(Stresnil, Janssen Pharmaceutical, Beerse, Belgium) and
medetomidine 25 μg/kg (Domitor, Pfizer, NY, USA) 20
minutes before induction. General anesthesia was
induced with intravenous fentanyl 4 μg/kg (Fentanyl
Torrex, Torrex Chiesi, Vienna, Austria) and etomidate
0.3 mg/kg (Hypnomidate, Janssen Pharmaceutica); then
the trachea was intubated. Positive pressure ventilation
was maintained (Siemens Servo 900 C ventilator,
Siemens, Elema, Sweden) in volume controlled mode,
with a fraction of inspired oxygen of 0.4, positive end
expiratory pressure of 5 cm H2O, frequency 16 breaths/
min, tidal volume 6–8 mL/kg so as to achieve normocapnia
(paCO2 4.6–5.3 kPa). Maintenance anesthesia was provided
using isoflurane (Forane, Abbott Laboratories, UK) with an
intravenous infusion of 6–10 μg/kg/h fentanyl. Neuro-
muscular blockade was achieved by means of boluses of
0.02 mg/kg pipecuronium bromide (Arduan, Gedeon
Richter, Budapest, Hungary) given throughout surgery.
Crystalloid and colloid solutions were used to support
the circulation and address hemorrhage; an infusion of
norepinephrine (Léčiva) was administered when needed.
The protocol for anesthesia and intravascular volume
therapy was the same in each experimental group.
Augmentin 1.2 g (amoxicillin and clavulanic acid,
SmithKline Beecham Pharmaceuticals, London, UK)
and famotidine 20 mg (Quamatel, Gedeon Richter) were
administered as antibiotic prophylaxis and to suppress
gastric acid secretion, respectively. Catheters were
inserted into the femoral artery and vein under direct
surgical vision to allow connection of the FPSA extra-
corporeal device, and to allow invasive blood pressure
monitoring and collection of blood samples. The in-
ternal jugular vein was identified surgically, and a
thermodilution pulmonary artery catheter (7F Arrow,
PA, USA) was positioned to monitor hemodynamic
variables.
Postoperative management
After liver resection, mechanical ventilation was changed
to pressure controlled mode, to achieve normocapnia with
a tidal volume of 6 to 8 mL/kg. The body temperature was
maintained between 36.5°C and 38.0°C using a forced-air
warming system (WarmAir, CSZ Medical). Subsequent
sedation and analgesia were provided by infusions of
propofol 6 mg/kg/h (Fresenius Kabi, Bad Homburg,
Germany) and fentanyl 2 mg/kg/h. Crystalloid and colloid
solutions were given as needed. Blood glucose concentra-
tion was maintained above 4.5 mmol/l using a continuous
infusion of 40% glucose solution (Braun). The circulation
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infusion to maintain a mean arterial pressure >65 mmHg.
Microdialysis and ICP monitoring
Microdialysis and ICP monitoring was initiated within
the first postoperative hour. Two burr holes were cre-
ated over the right frontal bone under sterile conditions.
The dura mater was punctured, and the microdialysis
membrane and ICP sensor were placed separately into
the frontal lobe. To prevent leakage of cerebrospinal
fluid (CSF), the burr holes were sealed with bone wax.
The CMA70 microdialysis catheter (CMA Solna
Sweden) consists of a thin, double lumen, 60 mm plastic
tube with a 10 mm semipermeable 20 kDa membrane at
the tip. After insertion into the brain tissue, the catheter
was connected to a microinfusion pump (CMA/106
Microinjection pump; CMA Microdialysis AB, Stockholm,
Sweden) and continuously perfused with artificial CSF at a
rate of 0.3 μL/min. The dialysate was collected in
microvials, each containing approximately 18 μL aliquots
for further analysis (CMA 600 Microdialysis Analyzer,
CMA Microdialysis). The analyzer measures glucose,
lactate, pyruvate and glutamate concentrations in each
sample, with >99% recovery when using a buffer of known
concentration at the selected perfusion rate [8,9]. We
collected dialysate samples every 60 min for analysis; the
first sample was collected during the second postoperative
hour. Specimens were frozen at −80°C for later analysis of
glutamine concentration using a Perkin-Elmer reverse-Figure 1 Intracranial pressure (ICP) following fractionated plasma sep
confidence intervals shown). Abbreviations: FPSA, fractionated plasma se
sham-operated controls.phase high pressure liquid chromatography system with
fluorescence detection and precolumn o-phthalaldehyde
derivatization [10]. ICP monitoring was performed using
an intraparenchymal sensor (Codan Microsensor, Johnson
and Johnson, USA).
FPSA treatment
The Prometheus extracorporeal system was primed with
0.9% NaCl, prior to its connection to the venous dialysis
catheter in the right femoral vein. The device eliminates
water-soluble and protein-bound toxins and breakdown
products of metabolism. In the FPSA circuit, venous
blood passes through a separator with a pore size of 250
kDa (AlbuFlow, Fresenius). The separated plasma than
passes through a neutral resin absorbent column
(Prometh01, Fresenius) and an anion exchange resin
absorber (Prometh02, Fresenius) to remove albumin-
bound toxins. The plasma phase is then returned to the
filter and dialyzed as whole blood in a high flow dialyzer
(F60S, Fresenius) to remove water-soluble toxins [11]
before being returned to the femoral vein. The treatment
was performed with a blood flow of 200 mL/min and a
plasma flow of 300 mL/min. Sodium citrate was used as
an anticoagulant. The dose of sodium citrate was deter-
mined according to serum ionized calcium concentration.
Statistical analysis
Regression models were constructed separately for each
parameter in each group of observations. The modelsaration and adsorption treatment (2–8 h) (curve fits with 95%
paration and adsorption; ALF, acute liver failure; SHAM,
Table 1 Intracranial pressure (ICP), lactate/pyruvate (L/P) ratio, extracellular brain glutamine, extracellular brain
glutamate, extracellular brain glucose and arterial ammonia following fractionated plasma separation and adsorption
(FPSA) treatment
Tme (h) 2 3 4 5 6 7 8 9 10 11 12
FPSA 7,53 8,77 10,29 11,93 13,58 15,09 16,33 17,17 17,47 17,10 15,92
SE 0,70 0,58 0,46 0,40 0,41 0,46 0,49 0,49 0,46 0,54 0,85
ICP ALF 7,94 9,46 10,98 12,49 14,01 15,53 17,05 18,57 20,09 21,61 23,13
(mmHg) SE 0,70 0,60 0,52 0,45 0,41 0,40 0,42 0,48 0,55 0,64 0,74
SHAM 8,58 8,73 8,97 9,31 9,74 10,22 10,70 11,12 11,40 11,43 11,09
SE 0,30 0,28 0,25 0,23 0,24 0,28 0,33 0,35 0,34 0,36 0,61
FPSAxALF 0,68 0,42 0,33 0,36 0,46 0,46 0,26 0,04 < 0,01 < 0,01 < 0,01
p values FPSAxSHAM 0,33 0,96 0,07 < 0,01 < 0,01 < 0,01 < 0,01 < 0,01 < 0,01 < 0,01 < 0,01
ALFxSHAM 0,58 0,47 0,02 < 0,01 < 0,01 < 0,01 < 0,01 < 0,01 < 0,01 < 0,01 < 0,01
FPSA 32,29 25,81 21,03 17,71 15,63 14,54 14,19 14,36 14,80 15,27 15,54
SE 2,98 1,70 1,62 1,65 1,54 1,49 1,63 1,79 1,73 1,69 2,83
L/P ratio ALF 22,19 22,00 21,81 21,62 21,43 21,24 21,05 20,86 20,67 20,47 20,28
SE 1,06 0,92 0,80 0,70 0,63 0,61 0,63 0,70 0,80 0,92 1,06
SHAM 9,88 9,92 9,96 10,00 10,03 10,07 10,11 10,15 10,19 10,23 10,26
SE 0,88 0,76 0,66 0,58 0,54 0,54 0,58 0,66 0,76 0,88 1,01
FPSAxALF <0,05 0,40 0,64 0,02 <0,01 <0,01 <0,01 <0,01 <0,01 <0,01 0,08
p values FPSAxSHAM <0,01 <0,01 <0,01 <0,01 0,02 0,05 0,10 0,12 0,08 0,05 0,05
ALFxSHAM <0,01 <0,01 <0,01 <0,01 <0,01 <0,01 <0,01 <0,01 <0,01 <0,01 <0,01
FPSA 0,66 0,92 1,08 1,17 1,20 1,19 1,20 1,27 1,48 1,90 2,66
SE 0,16 0,12 0,12 0,12 0,11 0,11 0,12 0,13 0,13 0,15 0,29
Extracellular brain ALF 1,08 1,23 1,37 1,52 1,66 1,81 1,95 2,10 2,24 2,39 2,53
glutamine SE 0,30 0,26 0,22 0,19 0,16 0,15 0,16 0,18 0,21 0,25 0,29
(μmol/L) SHAM 0,07 0,12 0,19 0,26 0,33 0,40 0,46 0,50 0,52 0,52 0,48
SE 0,09 0,08 0,06 0,04 0,03 0,04 0,04 0,04 0,04 0,04 0,07
FPSAxALF 0,21 0,27 0,25 0,12 0,02 <0,01 <0,01 <0,01 <0,01 0,09 0,76
p FPSAxSHAM 0,05 <0,01 <0,01 <0,01 <0,01 <0,01 <0,01 <0,01 <0,01 <0,01 <0,01
ALFxSHAM 0,07 0,02 <0,01 <0,01 <0,01 <0,01 <0,01 <0,01 <0,01 <0,01 <0,01
FPSA 19,82 16,22 13,20 10,77 8,93 7,69 7,03 6,97 7,49 8,61 10,32
SE 3,24 2,20 1,70 1,69 1,85 1,94 1,89 1,77 1,76 2,17 3,12
Extracellular brain glutamate ALF 29,65 28,83 28,01 27,19 26,38 25,56 24,74 23,92 23,11 22,29 21,47
(μmol/L) SE 6,50 5,58 4,74 4,04 3,55 3,37 3,55 4,04 4,74 5,58 6,50
SHAM 12,54 12,03 11,51 11,00 10,48 9,97 9,46 8,94 8,43 7,92 7,40
SE 2,03 1,76 1,52 1,33 1,21 1,20 1,28 1,45 1,68 1,94 2,23
FPSAxALF 0,22 0,06 0,01 <0,01 <0,01 <0,01 <0,01 <0,01 0,01 0,04 0,16
p values FPSAxSHAM 0,15 0,23 0,54 0,93 0,59 0,45 0,41 0,48 0,74 0,84 0,55
ALFxSHAM 0,12 0,08 0,04 0,02 0,01 0,01 0,01 0,03 0,07 0,13 0,20
FPSA 1,71 1,69 1,66 1,64 1,62 1,59 1,57 1,54 1,52 1,49 1,47
SE 0,27 0,23 0,20 0,17 0,15 0,15 0,16 0,18 0,21 0,24 0,28
Extracellular brain glucose ALF 1,52 1,50 1,46 1,41 1,35 1,27 1,19 1,09 0,99 0,87 0,74
(mmol/L) SE 0,12 0,12 0,11 0,10 0,09 0,08 0,08 0,09 0,10 0,12 0,15
SHAM 2,45 2,42 2,37 2,32 2,25 2,16 2,07 1,96 1,83 1,70 1,55
SE 0,13 0,13 0,12 0,11 0,10 0,09 0,09 0,11 0,13 0,16 0,20
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Table 1 Intracranial pressure (ICP), lactate/pyruvate (L/P) ratio, extracellular brain glutamine, extracellular brain
glutamate, extracellular brain glucose and arterial ammonia following fractionated plasma separation and adsorption
(FPSA) treatment (Continued)
FPSAxALF 0,49 0,42 0,33 0,21 0,11 0,05 0,02 0,01 0,01 0,01 0,02
p values FPSAxSHAM 0,09 0,05 0,03 0,02 0,01 0,02 0,05 0,15 0,34 0,60 0,86
ALFxSHAM <0,01 <0,01 <0,01 <0,01 <0,01 <0,01 <0,01 <0,01 <0,01 <0,01 0,01
FPSA 243,1 223,8 220,5 236,6 263,7 287,1 293,8 277,7 247,3 232 288,3
SE 28,96 29,04 26,88 25,65 29,04 31,18 28,09 31,05 47,24 52,05 33,53
Arterial ammonia ALF 235,2 271,5 302,3 327,7 347,6 362 371 374,5 372,6 365,2 352,3
(μmol/L) SE 24,2 26,39 28,48 29,67 29,68 28,61 26,94 25,77 26,86 31,84 41,05
SHAM 31,84 32,7 33,57 34,44 35,31 36,17 37,04 37,91 38,78 39n65 40n51
SE 3,78 3,48 3,29 3,24 3,33 3,57 3,91 4,34 4,82 5,36 5,93
FPSAxALF 0,83 0,23 0,05 0,03 0,05 0,09 0,06 0,02 0,02 0,02 0,26
p values FPSAxSHAM <0,01 <0,01 <0,01 <0,01 <0,01 <0,01 <0,01 <0,01 <0,01 <0,01 <0,01
ALFxSHAM <0,01 <0,01 <0,01 <0,01 <0,01 <0,01 <0,01 <0,01 <0,01 <0,01 <0,01
SE standard error.
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fitted intercepts; terms were calculated using the least
squares method. The model was developed by initially
including all terms, then the term with the lowest sig-
nificance was sequentially removed until all terms dem-
onstrated significance on an α = 5% level. The intercept
was not removed. The first-degree term was retained in
models where none of the terms demonstrated signifi-
cance. The fits were calculated for the chosen time
points, including the standard error, and 95% confidence
intervals (95%CI). In addition, analysis of variance
(ANOVA) was undertaken using the same model. For
each given time point, a two-sample t-test was under-
taken to examine the following hypotheses: H0, the
difference between fits was not significant; H1, the
difference between fits was significant. The t-test was
calculated using the following parameters: mean differ-
ence (difference between the compared fits); degrees of
freedom (degrees of freedom corresponding to the error
term in ANOVA, i.e. the number of observations minus
the number of terms included in the regression model);
and standard deviation (standard error of the fit multi-
plied by the square root of [degrees of freedom +1]). A
p-value (the smallest level to conclude significance) was
calculated from the test statistic T. The acceptability of
the alternative hypothesis was evaluated on an α = 5%
level (p <0.05). The regression model was developed in
Q-DAS Destra v.10 (Q-DAS Asset GmbH & Co. KG,
Weinheim, Germany). The fits and associated parame-
ters were calculated in Minitab 16.2.2. The t-test was
performed and data plotted using Microsoft MS Excel
2010.
Preoperative treatment, surgery and postoperative care
were undertaken according to the protection against
cruelty to animals, law no. 312/2008 Coll., and theprotection, breeding and the use of experimental ani-
mals, decree no. 207/2004 Coll. The study was approved
by the experts and ethics committee of the Institute of




The ICP was significantly higher (p <0.05) in the ALF
group between hours 9–12 when compared with the
FPSA-treated group. After 5 hours, ICP was significantly
higher (p <0.05) in the ALF and FPSA groups compared
with the SHAM group (Figure 1, Table 1); however,
the magnitude of the increase was significantly smaller
(p <0.05) in the FPSA than the ALF group.
Microdialysis parameters
There was a significant decrease in the lactate to pyru-
vate ratio (L/P ratio) in the FPSA group, but not in the
ALF or SHAM groups. The L/P ratio was significantly
higher in the ALF group than the SHAM group between
2 hours and 12 hours after surgery from (p <0.01), and
significantly lower in the FPSA group than the ALF
group between 5 hours and 11 hours after surgery
(p <0.05). Comparing the FPSA and the SHAM groups,
The L/P ratio was significantly higher in the FPSA group
than the SHAM group between 2 hours and 7 hours, and
from 11 hours after surgery (p <0.05, Figure 2, Table 1).
The extracellular brain glutamine concentration was
significantly higher in both the ALF and FPSA groups
compared with the SHAM group from 2 hours to 12
hours after surgery, and 3 hours to 12 hours after surgery,
respectively (p <0.05; p <0.02). Glutamine concentrations
were significantly lower in the FPSA group compared
with the ALF group from 6 hours to 10 hours after
Figure 2 Extracellular brain lactate/pyruvate ratio following fractionated plasma separation and adsorption treatment (2–8 h) (curve
fits with 95% confidence intervals shown). Abbreviations: FPSA, fractionated plasma separation and adsorption; ALF, acute liver failure; SHAM,
sham-operated controls.
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significantly higher (p <0.05) in the ALF than in the
FPSA group (Figure 3, Table 1). Extracellular brain
glutamate concentrations were significantly higher in
the ALF group than the FPSA group between 4 hours
and 11 hours after surgery (p <0.05), and the SHAM
group between 4 hours and 9 hours after surgery
(p <0.05). Glutamate concentration was higher in the
FPSA group than the SHAM group between 2 hours
and 4 hours after surgery, lower between 5 hours and
10 hours, and higher again between 11 hours and 12
hours after surgery but the difference was not signifi-
cant (Figure 4, Table 1). The extracellular brain glucose
concentration was significantly higher in the SHAM
group than either the ALF or the FPSA groups 2 hours
to 12 hours after surgery and 3 hours to 7 hours after
surgery, respectively (p <0.05 for both). The extracellu-
lar glucose level was significantly higher (p <0.05) in the
FPSA group compared with the ALF group from 7
hours after surgery (Figure 5, Table 1).
Plasma ammonia
The plasma ammonia concentration was significantly
higher in the FPSA and ALF groups than the SHAM
group, and higher in the ALF group than the FPSA
group between 5 hours and 6 hours, and between 9
hours and 11 hours after surgery (p <0.05) (Figure 6,
Table 1). Compared with baseline values, plasma ammo-
nia was significantly lower in the FPSA group than theALF group from 4 hours. In the SHAM and FPSA
groups, plasma ammonia concentrations were not sig-
nificantly elevated, but there was a significant increase
(p <0.05) in the ALF group.
Discussion
ALF carries a high mortality rate [12], frequently precipi-
tating multiorgan failure (MOF) regardless of the cause.
The onset of ALF is accompanied by hepatic encephal-
opathy and cerebral edema, leading to a rise in ICP.
Intracranial hypertension, brain injury and MOF are the
most common causes of death in ALF [13]. Intracranial
hypertension in ALF is caused by the swelling of brain
cells, particularly astrocytes [14], as a consequence of
the accumulation of toxic metabolites that have not been
cleared by the liver, and by cerebral hyperemia, caused
by disruption of the autoregulation of cerebral blood
flow [15]. Liver transplantation may afford the only
chance of a cure in many patients with fulminant ALF.
Various bridging therapy procedures have been proposed
to overcome the critical period before transplantation.
The FPSA method attenuates the rise in ICP caused by
ALF.
Cerebral microdialysis allows accurate monitoring of
the contents of the extracellular space [16]. The L/P
ratio is a well-recognized marker of the redox state of
the tissue and an indicator of tissue ischemia [17], and
in the brain reflects the metabolic state of astrocytes.
Other markers of cellular homeostasis routinely detected
Figure 3 Extracellular brain glutamine concentration following fractionated plasma separation and adsorption treatment (2–8 h) (curve
fits with 95% confidence intervals shown). Abbreviations: FPSA, fractionated plasma separation and adsorption; ALF, acute liver failure; SHAM,
sham-operated controls.
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information about pathological processes in brain tissue.
The amino acid glutamate, the main excitatory neuro-
transmitter released upon neuronal excitation, is consid-
ered to be an indirect marker of neuronal tissue distress.
We found that the L/P ratio decreased significantly
and almost immediately after the start of FPSA treat-
ment, reflecting a return to the normal metabolic state
of the brain, although it is notable that the ratio was
high immediately after surgery. Presumably this reflects
the extent of surgical stress and hepatic impairment,
although this was the same for animals in the FPSA and
ALF groups. Within 6 hours, the L/P ratio in the FPSA
group had fallen to match that of the SHAM controls,
but there was no decrease in the ALF group. Later,
between 10 and 12 hours, the L/P ratio in the FPSA
group rose again until it was similar to the ALF group,
suggesting that the benefit of FPSA treatment wanes
over time. Significant differences in the L/P ratio were
seen between the FPSA and ALF groups 1 hour after
treatment, although surprisingly it was higher in the
FPSA group. It is probable that the first specimens
contained dialysate collected during equilibration just
after insertion of the ICP and microdialysis catheters,and that our conclusions about early observations may
be limited by early direct trauma to the brain during
placement of the devices [18].
In contrast to the clinical trial studying the effect of
FPSA on oxidative metabolism in patients with ALF
conducted by Bjerring and colleagues [5], we found a
significant difference between the treated and control
groups and a significant decrease in the L/P ratio in the
treated group. This could be explained by our use of a
well-defined and predictable animal model with a con-
trol group, whereas the etiology of ALF varied in the co-
hort of patients enrolled in the clinical trial. We were
also able to control the timing of sampling and the FPSA
treatment in relation to the induction of ALF precisely,
which is more challenging in clinical practice, and to
collect microdialysate samples hourly rather than be-
fore and after treatment. The reporting of the clinical
trial is also unclear about the definition of completion
of treatment, and whether some of the dialysate might
have been collected before FPSA was complete as the
perfusion rate used equated to a sampling period
exceeding 5 hours. As the L/P ratio changes rapidly
during FPSA treatment, our results are likely to be
more informative.
Figure 5 Extracellular brain glucose concentration following fractionated plasma separation and adsorption treatment (2–8 h) (curve
fits with 95% confidence intervals shown). Abbreviations: FPSA, fractionated plasma separation and adsorption; ALF, acute liver failure; SHAM,
sham-operated controls.
Figure 4 Extracellular brain glutamate concentration following fractionated plasma separation and adsorption treatment (2–8 h)
(curve fits with 95% confidence intervals shown). Abbreviations: FPSA, fractionated plasma separation and adsorption; ALF, acute liver failure;
SHAM, sham-operated controls.
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Figure 6 Arterial ammonia concentration following fractionated plasma separation and adsorption treatment (2–8 h) (curve fits with
95% confidence intervals shown). Abbreviations: FPSA, fractionated plasma separation and adsorption; ALF, acute liver failure; SHAM, sham-
operated controls.
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groups, and was significantly higher than in the SHAM
group from 5 hours onwards. The ICP was significantly
higher in the ALF group compared with the FPSA group
from the ninth hour. The rise in ICP observed in the
FPSA group, even if it was significantly less than the
ALF group, suggests a multiple causes for the intracra-
nial hypertension associated with ALF [14], which can
only be partially ameliorated by the supporting toxin-
eliminating method. Our findings support the conclu-
sions of previous studies and confirm the efficacy of
toxin elimination in as a treatment for intracranial
hypertension in ALF [3]. The most significant difference
between the ICP measured in the FPSA and control
groups was observed 9 hours after surgery (7 hours after
initiation of FPSA therapy). Thus, the L/P ratio appears
to reflect the positive influence of FPSA treatment on
cerebral metabolism more promptly than ICP.
ICP tends to change gradually, but substantial and sig-
nificant changes in L/P ratio were evident almost imme-
diately after FPSA treatment. This suggests that FPSA is
having an almost immediate beneficial effect on cerebral
metabolism, and that L/P ratio may be a more useful
means of guiding interventions in clinical practice [19].
Correlations between intracerebral glutamine concen-
tration, ICP and arterial ammonia concentration have
been reported in clinical studies of ALF [20]. Ammonia
crosses the blood–brain barrier easily and increases
brain glutamine levels by accelerating its synthesis,predominantly by astrocytes [21]. Intracellular accumu-
lation of glutamine in the astrocytes causes osmotic cell
swelling and high ICP [22]. In vitro studies suggest that
glutamine might also cause metabolic failure within
mitochondria, having been transported into mitochon-
dria where it is metabolized to glutamate and ammonia
[23]. This in turn triggers mitochondrial permeability
transition and gives rise to free radical production, both
of which contribute to astrocyte swelling and brain
edema [24]. Elevated intracellular glutamine concentra-
tion is thought to be one of the most important causes
of mitochondrial distress and intracellular hypoxia in
ALF. Our data clearly show a positive influence of FPSA
on the cerebral accumulation of glutamine, and support
the hypothesis that accumulation of cerebral glutamine
contributes to intracranial hypertension in ALF. More-
over, our findings are consistent with those in patients
with ALF in which correlations between cerebral glu-
tamine, ICP and the L/P ratio were evident [25]. Signifi-
cantly lower concentrations of glutamine were observed
in the FPSA group compared with the ALF group 6
hours after surgery, 3 hours before significant differences
in ICP became evident. However, glutamine assays are
technically difficult and bedside testing is not readily
available; further research is needed to establish the
clinical utility of brain glutamine measurement.
We found a significant difference between the glutam-
ate levels in the ALF and FPSA groups from 4 hours to
11 hours after surgery; the change in glutamate in the
Prazak et al. BMC Gastroenterology 2013, 13:98 Page 10 of 11
http://www.biomedcentral.com/1471-230X/13/98FPSA group resembled the change in the L/P ratio.
However, there was only a slight difference between the
ALF and SHAM groups; glutamate was higher in the
ALF group, but only significantly so between 4 hours
and 9 hours after surgery. Moreover, there was no
significant difference between the FPSA and the SHAM
group. These results exclude glutamate as a reliable marker
in monitoring the efficacy of the treatment of ALF.
Extracellular brain glucose was higher in the SHAM
group than in the ALF or FPSA groups. Although un-
common in ALF, similar findings have been reported be-
fore [26]. Nevertheless, when we compared the changes
in extracellular brain glucose from baseline, there were
no significant differences between the groups, suggesting
that FPSA does not influence cerebral extracellular glu-
cose levels.
Plasma ammonia levels were significantly higher in
both the ALF and FPSA groups than the SHAM group,
and the difference between the FPSA and ALF groups
was also significant. As there is a relatively wide range of
accepted physiological values for plasma ammonia, we
also compared the values relative to baseline. This com-
parison showed a significant difference between the
FPSA and ALF groups as early as 4 hours after surgery,
demonstrating the efficacy of FPSA therapy.
Conclusions
FPSA treatment significantly attenuates the development
of intracranial hypertension and decreases plasma am-
monia levels, both of which are fundamental to the
pathophysiological processes that underpin ALF.
Cerebral microdialysis is a valuable and promising
technique; the L/P ratio and intracerebral glutamin
reflected the beneficial effects of FPSA treatment on
cerebral metabolism more quickly than ICP in our
experimental model of ALF.
Glutamate did not show significant changes, and thus
its clinical use cannot presently be recommended. How-
ever, the role of glutamine as a clinical marker of the
efficacy of treatment warrants further investigation.
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